PRICE T ROWE ASSOCIATES INC /MD/ - GENMARK DIAGNOSTICS INC ownership

GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 105 filers reported holding GENMARK DIAGNOSTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of GENMARK DIAGNOSTICS INC
ValueSharesWeighting
Q1 2021$4,331,000
-84.2%
181,226
-90.3%
0.00%
-100.0%
Q4 2020$27,332,000
+0.6%
1,872,073
-2.1%
0.00%0.0%
Q3 2020$27,156,000
-5.1%
1,912,424
-1.7%
0.00%
-25.0%
Q2 2020$28,625,000
+227.7%
1,945,978
-8.2%
0.00%
+300.0%
Q1 2020$8,735,000
-14.1%
2,120,047
+0.3%
0.00%0.0%
Q4 2019$10,166,000
-44.1%
2,113,579
-29.6%
0.00%
-66.7%
Q3 2019$18,181,000
-57.5%
3,000,151
-54.5%
0.00%
-50.0%
Q2 2019$42,766,000
-21.6%
6,589,491
-14.3%
0.01%
-25.0%
Q1 2019$54,530,000
+37.8%
7,691,133
-5.6%
0.01%
+14.3%
Q4 2018$39,582,000
-37.8%
8,144,394
-5.9%
0.01%
-22.2%
Q3 2018$63,631,000
+12.6%
8,657,319
-2.3%
0.01%0.0%
Q2 2018$56,513,000
+16.9%
8,857,766
-0.3%
0.01%
+12.5%
Q1 2018$48,351,000
+31.3%
8,888,010
+0.6%
0.01%
+33.3%
Q4 2017$36,828,000
-42.0%
8,831,638
+33.8%
0.01%
-45.5%
Q3 2017$63,545,000
+8.3%
6,598,608
+33.0%
0.01%0.0%
Q2 2017$58,680,000
+14.3%
4,960,231
+23.8%
0.01%
+10.0%
Q1 2017$51,361,000
+8.2%
4,006,320
+3.3%
0.01%
+11.1%
Q4 2016$47,489,000
+6.7%
3,879,814
+2.9%
0.01%0.0%
Q3 2016$44,502,000
+91.7%
3,771,354
+41.3%
0.01%
+80.0%
Q2 2016$23,218,000
+65.0%
2,668,754
-0.1%
0.01%
+66.7%
Q1 2016$14,072,000
-29.8%
2,670,154
+3.4%
0.00%
-25.0%
Q4 2015$20,043,000
+0.5%
2,582,854
+1.9%
0.00%0.0%
Q3 2015$19,945,000
-14.2%
2,534,354
-1.2%
0.00%
-20.0%
Q2 2015$23,235,000
-30.2%
2,564,554
+0.1%
0.01%
-28.6%
Q1 2015$33,268,000
-4.8%
2,563,054
-0.2%
0.01%0.0%
Q4 2014$34,961,000
+50.7%
2,568,754
-0.7%
0.01%
+40.0%
Q3 2014$23,203,000
-33.6%
2,586,754
+0.2%
0.01%
-37.5%
Q2 2014$34,939,000
+32.1%
2,582,354
-2.9%
0.01%
+33.3%
Q1 2014$26,439,000
-62.6%
2,659,900
-49.9%
0.01%
-25.0%
Q4 2013$70,678,000
+38.1%
5,310,200
+26.0%
0.01%
-38.5%
Q3 2013$51,195,000
-36.4%
4,213,600
-45.9%
0.01%
+18.2%
Q2 2013$80,522,0007,787,4000.01%
Other shareholders
GENMARK DIAGNOSTICS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Versor Investments LP 2,664,831$63,689,0003.80%
Chicago Capital Management, LLC 318,113$7,603,0003.54%
First Trust Capital Management L.P. 564,758$13,498,0002.64%
WATER ISLAND CAPITAL LLC 1,693,162$40,467,0002.47%
Sand Grove Capital Management LLP 992,068$23,710,0002.31%
EMC Capital Management 121,023$2,892,0002.06%
OMNI PARTNERS LLP 1,540,671$36,822,0001.82%
TIG Advisors, LLC 1,774,849$42,419,0001.60%
Cowen Prime Services LLC 174,850$4,179,0001.58%
G2 Investment Partners Management LLC 396,400$9,474,0001.50%
View complete list of GENMARK DIAGNOSTICS INC shareholders